Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × tapotoclax × Clear all
NCT05209152 2025-07-14

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Amgen

Phase 1 Terminated
7 enrolled 16 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02675452 2025-07-09

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Amgen

Phase 1 Terminated
141 enrolled 46 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute

NCT03797261 2021-12-07

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

AbbVie

Phase 1 Terminated
9 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡